Chandra Lukman Ade, Nirwati Hera, Nugroho Dhite
Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Department of Microbiology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Indian J Med Res. 2024;160(3&4):362-370. doi: 10.25259/IJMR_992_2024.
Background & objectives The COVID-19 pandemic has led to unprecedented global immunization efforts, with drive-through vaccination campaigns established to expedite and ensure safe coverage. However, research on immediate adverse events following immunization (AEFI) in these settings is limited. This study aims to evaluate the frequency and characteristics of immediate AEFI during drive-through COVID-19 vaccination campaigns in Yogyakarta, Indonesia, using the Sinovac/CoronaVac vaccine Methods This cross-sectional study utilized secondary data from the local vaccine registry managed by the Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Indonesia, from July 27 to September 6, 2021. Participants included individuals aged over 11 yr without underlying medical conditions such as diabetes, hypertension, cancer, or asthma. Key characteristics recorded were age, gender, and AEFI. Results Out of 27,459 registrants, only 20,817 were eligible and received a dose. The median participant age was 20 yr (IQR 10); 47 per cent were male (9,712) and 53 per cent female (11,105). The highest vaccination day was September 6, 2021, with 3,883 doses (18%). Among the 79 participants who experienced AEFI [0.38%; 95% Confidence Interval (CI): 0.30-0.47], the median age was 19 yr (IQR 8); 41 per cent were male (34) and 59 per cent female (48). Systemic adverse events (92%) were more common than local events (6.3%), with dizziness (77.2%) being most prevalent. Interpretation & conclusions The findings of this study suggest that immediate AEFI occurred rarely in the drive-through vaccination setting, indicating that this method appears safe and efficient for COVID-19 vaccinations, particularly in the context of immediate AEFI. Most adverse events were mild, underscoring the importance of preparedness and close monitoring in drive-through vaccination campaign sites to ensure patient safety and enhance vaccine confidence.
新冠疫情引发了前所未有的全球免疫接种行动，设立了免下车接种活动以加快并确保安全接种覆盖率。然而，在这些情况下关于免疫接种后立即出现的不良事件（AEFI）的研究有限。本研究旨在评估印度尼西亚日惹市免下车新冠疫苗接种活动期间立即出现的AEFI的频率和特征，使用的是科兴/克尔来福疫苗。方法：这项横断面研究利用了印度尼西亚加查马达大学医学、公共卫生与护理学院管理的当地疫苗登记处2021年7月27日至9月6日的二手数据。参与者包括年龄超过11岁且无糖尿病、高血压、癌症或哮喘等基础疾病的个体。记录的关键特征为年龄、性别和AEFI。结果：在27459名登记者中，只有20817人符合条件并接种了一剂疫苗。参与者的年龄中位数为20岁（四分位距10）；47%为男性（9712人），53%为女性（11105人）。接种量最高的一天是2021年9月6日，接种了3883剂（18%）。在79名出现AEFI的参与者中[0.38%；95%置信区间（CI）：0.30 - 0.47]，年龄中位数为19岁（四分位距8）；41%为男性（34人），59%为女性（48人）。全身不良事件（92%）比局部事件（6.3%）更常见，其中头晕（77.2%）最为普遍。解读与结论：本研究结果表明，在免下车接种环境中立即出现的AEFI很少发生，这表明这种方法对于新冠疫苗接种似乎是安全有效的，尤其是在立即出现AEFI的情况下。大多数不良事件为轻度，这凸显了在免下车接种活动地点做好准备和密切监测以确保患者安全并增强疫苗信心的重要性。
